Drug Trial Radar · NCT06824181
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
580
Actual
Start
Feb 27, 2025
Primary completion
Sep 10, 2027
Study completion Sep 10, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age (MoA). Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.
Conditions
- Pneumococcal Immunization
Interventions
PCV21 vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Prevnar 20 vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
M-M-R II vaccineBiological
Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
RotarixBiological
Pharmaceutical form:Solution-Route of administration:Oral
RotaTeqBiological
Pharmaceutical form:Solution-Route of administration:Oral
Vaxelis vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
VarivaxBiological
Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
PriorixBiological
Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
VAQTABiological
Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
HavrixBiological
Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of any immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
- Presence of solicited injection site and systemic reactions through 7 days after each vaccine injectionTime frame: Through 7 days after each vaccine injection
- Presence of unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs through 30 days after each vaccine injectionTime frame: Through 30 days after each vaccine injection
- Presence of serious adverse events (SAEs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months
- Presence adverse events of special interest (AESIs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months
- Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days PD4Time frame: 30 days PD4
Locations
27 sites in 4 countries. Site status is shown where the registry gives one.
Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400025
Los Angeles, California
The Medici Medical Research- Site Number : 8400008
Hollywood, Florida
Clinsearch Inc at Dr. Gala, LLC- Site Number : 8400027
Miami, Florida
Atlantis Clinical Research- Site Number : 8400009
Miami, Florida
Velocity Clinical Research - Sioux City- Site Number : 8400007
Sioux City, Iowa
Private Practice - Dr. Michael W. Simon- Site Number : 8400001
Lexington, Kentucky
Velocity Clinical Research - New Orleans- Site Number : 8400006
New Orleans, Louisiana
Finger Lakes Medical Research - Cortland- Site Number : 8400022
Cortland, New York
University of Rochester Medical Center- Site Number : 8400019
Rochester, New York
SUNY Upstate Medical University - Syracuse- Site Number : 8400015
Syracuse, New York
Kid's Way Pediatrics- Site Number : 8400013
Hermitage, Pennsylvania
Carolina Family Care - Charleston- Site Number : 8400014
Charleston, South Carolina
Helios Clinical Research - BUR PEDI- Site Number : 8400016
Burleson, Texas
Clinsearch Inc at VAST Clinical Research- Site Number : 8400028
Euless, Texas
DM Clinical Research - Houston - Jones Road- Site Number : 8400012
Houston, Texas
University of Texas Medical Branch at Galveston- Site Number : 8400005
League City, Texas
Javara - Privia Medical Group North Texas - Stephenville- Site Number : 8400024
Stephenville, Texas
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 4840003
León, Guanajuato, Mexico
Investigational Site Number : 4840001
Mexico City, Mexico City, Mexico
Investigational Site Number : 4840002
Temixco, Morelos, Mexico
Investigational Site Number : 4840004
Tlaltizapán, Morelos, Mexico
Investigational Site Number : 6080001
Cebu City, Philippines
Investigational Site Number : 6080002
Quezon City, Philippines
Investigational Site Number : 6080003
Quezon City, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.